<DOC>
	<DOCNO>NCT02009462</DOCNO>
	<brief_summary>Artefill injectable facial filler device currently approve FDA correction nasolabial fold . This study seek examine use Artefill treatment HIV associate facial lipoatrophy . Facial lipoatrophy ( facial fat loss ) relate HIV stigmatize condition characterize loss facial fat , notably cheek temple .</brief_summary>
	<brief_title>Artefill Treatment HIV-associated Facial Lipoatrophy</brief_title>
	<detailed_description>The objective study : To evaluate long-term safety Artefill injection volume three four time great ( i.e . 30 ml ) volume indicated FDA approve product label ( i.e . 8.9 ml ) subject HIV . To evaluate adverse event associate use Artefill . To evaluate Quality Life body image benefit Artefill treatment patient lipoatrophy .</detailed_description>
	<mesh_term>Facies</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Polymethyl Methacrylate</mesh_term>
	<criteria>1 . Subject male female 1880 year age inclusive time signing informed consent . 2 . Subject desire treatment facial volume loss . 3 . Subject HIV infection moderate severe facial lipoatrophy base Modified James Scale grade IIIV . 4 . Subject viral load &lt; 400 copies/mL . 5 . Subject CD4 lymphocyte count &gt; 200/mm . 6 . Subject document negative Artefill skin test receive treatment Artefill past without evidence hypersensitivity reaction . 7 . Subject willing withhold additional aesthetic implant therapy ( eg , soft tissue filler Restylane , silicone , Radiesse , Sculptra implant Gortex , Silastic , etc ) duration study . 1 . Subject skin pathology , inflammatory skin disease , condition could interfere evaluation treatment area . 2 . Subject history systemic granulomatous disease ( sarcoid , Wegeners , etc ) connective tissue disease ( lupus , dermatomyositis , ect ) 3 . Subject history keloid formation hypertrophic scarring . 4 . Subject history malignancy ( skin cancer ) within 12 month enrollment . 5.Subject treated systemic corticosteroid ( eg , prednisone ) interferon within 1 month prior study enrollment 6 . Subject thrombocytopenia bleeding diathesis . 7 . Subject pregnant , plan become pregnant , breastfeed . 8..Subject treat follow within time interval specify prior start participation study : Bovine collagen6 month Hyaluronic acid6 month Calcium hydroxylapatite6 month Polyacrylamideat time Polylactic acid 6 month Permanent implant graft time . 9 . Subject severe allergy manifest history anaphylaxis history presence multiple severe allergy . 10 . Subject know hypersensitivity lidocaine . 11 . Subject history allergy bovine collagen product . 12 . Subject undergo planning undergo desensitization injection meat product . 13 . Subject condition , investigator 's opinion , would make unsafe subject participate research study . 14 . Subject substance abuse , depression , issue , accord investigator 's judgment , would interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Facial lipoatrophy</keyword>
</DOC>